This ADC product is composed of an anti-CD19 antibody (clone huB4) conjugated via mc linker to MMAF (huB4-mc-MMAF). It is in Phase I clinical trials and has demonstrated a response in B-cell lymphoma treatment by a MOA (Mechanism of Action) of microtubules depolymerizing.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-174 | Mouse Anti-CD19 Recombinant Antibody (clone Taplitumomab) | ELISA, IP, FC, FuncS, Neut, IF, ICC | Mouse IgG1, κ |
TAB-1611CL | Mouse Anti-CD19 Recombinant Antibody (TAB-1611CL) | Depletion, FuncS | Mouse IgG2a, κ |
TAB-1620CL | Anti-Human CD19 Recombinant Antibody (HD37) | FuncS | |
TAB-1622CL | Mouse Anti-CD19 Recombinant Antibody (TAB-1622CL) | ELISA, FC, Apop, ADCC, FuncS | Mouse IgG |
TAB-1623CL | Mouse Anti-CD19 Recombinant Antibody (TAB-1623CL) | ELISA, FC | Mouse IgG |
There are currently no Customer reviews or questions for ADC-045LZY. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.